Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
ADCT
ADCT
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ADCT News
ADC Therapeutics Grants Stock Options to New Employees
Feb 02 2026
PRnewswire
Oncolytics Biotech Strengthens Leadership Amid FDA Approval Surge
Jan 30 2026
PRnewswire
Oncolytics Biotech Strengthens Leadership Amid FDA Approval Surge
Jan 30 2026
Newsfilter
ADC Therapeutics Faces Securities Fraud Investigation, Stock Drops 14.13%
Jan 20 2026
Globenewswire
ADC Therapeutics Faces Securities Fraud Investigation as Stock Drops 14.13%
Jan 13 2026
Globenewswire
ADC Therapeutics Reports $73M Net Revenue for 2025 with Strong Cash Position
Jan 08 2026
Newsfilter
ADC Therapeutics Faces Securities Fraud Claims, Stock Drops 14.13%
Jan 08 2026
PRnewswire
ADC Therapeutics CEO Ameet Mallik to Present at J.P. Morgan Healthcare Conference on January 15, 2026
Jan 08 2026
PRnewswire
ADC Therapeutics CEO Ameet Mallik to Present at J.P. Morgan Healthcare Conference on January 15, 2026
Jan 08 2026
Newsfilter
ADC Therapeutics Grants 6,000 Stock Options to New Employee as Inducement
Jan 02 2026
PRnewswire
ADC Therapeutics Grants 6,000 Stock Options to New Employee as Inducement
Jan 02 2026
Newsfilter
ADC Therapeutics Faces Securities Fraud Investigation as Stock Plummets 14.13%
Jan 01 2026
PRnewswire
ADC Therapeutics Faces Securities Fraud Investigation as Stock Plummets 14.13%
Dec 30 2025
Globenewswire
GT Biopharma Advances GTB-3650 Clinical Trial to Cohort 4 with 10μg/kg/day Dosing
Dec 19 2025
PRnewswire
GT Biopharma Advances GTB-3650 Clinical Trial to Cohort 4 with 10μg/kg/day Dosing
Dec 19 2025
Newsfilter
Is ADC Therapeutics SA (ADCT) a Strong Momentum Stock Worth Buying?
Dec 15 2025
NASDAQ.COM
Show More News
